OptimizeRx Corporation Third Quarter 2026 Conference Call - OPTIMIZERX CORP

Financial Performance:

• Q3 2026 revenue was $21.6 million, down 17% year-over-year due to reduced spending from key large customers and market budget scrutiny.
• Adjusted EBITDA reached $6.3 million (approx. 29% margin), up from $5.1 million (20% margin) in Q3 2025, driven by disciplined cost management and favorable product mix.
• Net income for Q3 2026 was $1.2 million ($0.06/share), compared to $0.8 million ($0.04/share) in the prior year; non-GAAP net income was $3.8 million ($0.20/share).
• Gross margin is expected to remain in the low 70% range for the full year 2026.
• Operating cash flow for the first nine months of 2026 was $12.9 million; cash balance ended the quarter at $22.3 million.
• Debt was significantly reduced to $10.4 million following a $6.3 million principal payment in Q3 (paying $6 million ahead of schedule) and an additional $3 million post-quarter payment.
• Net Revenue Retention (NRR) dipped to 83% due to a large client (representing ~10% of business) not generating revenue in the first three quarters, though this client has resumed spending in Q4.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance lowered to $87–$93 million (previously higher) due to contracted revenue tracking ~20% below prior year levels and timing of customer spend decisions.
• Full-year 2026 Adjusted EBITDA guidance maintained at $21–$25 million, reflecting confidence in margin expansion and cost control.
• 2027 RFP season contracted revenue is tracking ~20% ahead of prior year levels, indicating strong pent-up demand and renewed customer engagement.
• Management anticipates a recovery in growth metrics for 2027, aligning more closely with 2025 growth rates rather than 2026's decline, as the displaced large client returns to normal spend levels.
• No formal 2027 guidance provided yet, but management expresses high confidence in double-digit growth driven by new product adoption and programmatic expansion.

Business Segments and Product Lines:

• Programmatic Distribution: Established partnerships with three major Demand-Side Platforms (DSPs): DeepIntent, The Trade Desk (Open Path), and PulsePoint, integrating over 1.1 million verified HCPs across 450+ EHR systems.
• AI & Data Products: Launched enhancements to Natural Language Audience Builder (NLAB) for privacy-safe DTC targeting; introduced COPEQ solution; continued scaling of Demand-Access Platform (DAP).
• Customer Mix: Notable progress in mid-tier and long-tail life science customers; one mid-tier client expanded into the top 10 client pool.
• Commercial Leadership: Appointed Sarah Bass as Chief Marketing Officer to strengthen go-to-market execution and agency partnerships.
• Finance Leadership Transition: CFO Ed Stelmach remains through 2026; Andy DeSilva assumes CFO role and Heather Favaza becomes Chief Accounting Officer effective January 1, 2027.

Market and Competitive Landscape:

• Pharma Environment: Customers facing budget scrutiny, MFN pricing uncertainty, and political volatility, leading to delayed spending decisions and "warehoused" budgets.
• Competitive Moat: Unique positioning as the only tech company with an AI-enabled operating system, proprietary healthcare data, and authenticated EHR network.
• Differentiation: Capabilities in predictive audience intelligence and programmatic activation differentiate from general-purpose AI and traditional direct-sales models.
• Market Share: Integrations with leading DSPs capture an estimated 60–70% of the available programmatic volume in the space.

Risks and Challenges:

• Revenue Timing: Significant execution risk in Q4 to recognize contracted revenue, as the $6–9 million gap from the displaced client must be recovered before year-end.
• Customer Concentration: Reliance on a limited number of large accounts; the pullback from one major client significantly impacted Q3 metrics and NRR.
• Visibility: Lack of immediate visibility into "buy-up" activity for year-end spending despite strong 2027 RFP pipeline.
• Regulatory/Political: Potential impacts from shifting political administrations and drug pricing policies (e.g., MFN) on pharma marketing budgets.
• Debt: While debt levels are low, continued adherence to the repayment schedule is required alongside share repurchase plans.

Management Commentary and Tone:

• Tone: Cautiously optimistic; management acknowledges revenue headwinds but emphasizes strong profitability, margin expansion, and a robust pipeline for 2027.
• Confidence: High confidence in the long-term value of proprietary data and AI platforms; management attributes 2026 revenue misses to timing rather than fundamental demand issues.
• Strategic Focus: Priorities include improving top-line execution in Q4, expanding AI product adoption (DAP, NLAB), and scaling programmatic distribution for 2027.
• Transparency: Management committed to clear communication regarding guidance changes, citing the inability to over-promise on uncertain Q4 buy-up activity.

Analyst Questions and Answers:

• Programmatic Runway: Management confirmed DeepIntent, Trade Desk, and PulsePoint represent ~60–70% of the programmatic volume, with early positive results in volume and bidding.
• NRR Recovery: Confirmed 83% NRR was driven by one client's absence; management expects NRR to normalize significantly in 2027 as the client returns and mid/long-tail growth accelerates.
• 2027 Growth Floor: Declined to provide a specific 2027 floor but noted contracted revenue is 20% ahead, suggesting a return to growth rates similar to 2025.
• Mid/Long-Tail Growth: Reported "very encouraging" play and double-digit growth in non-top 20 segments, including MedTech.
• Debt vs. Buybacks: Management indicated a strategic shift to accelerate stock buybacks in Q4 after aggressively paying down debt.
• Political Impact: Clients are uncertain regarding the new political administration and drug pricing policies, causing recalibration of budgets.
• 4Q Revenue Composition: ~90% of the full-year midpoint guidance is currently contracted, leaving a smaller but expected gap to be filled by Q4 buy-ups.

Other Key Points:

• One Client Return: A previously displaced top-five client has returned in Q4, generating revenue from non-budgeted dollars, signaling renewed engagement.
• Margin Expansion: Despite revenue decline, the 900 basis point increase in adjusted EBITDA margin validates the operating leverage of the cost-reduction initiatives.
• Product Evolution: Transitioning from a traditional point-of-care marketing business to a technology platform supporting audience intelligence, media planning, and programmatic activation.
• Strategic Partnerships: New integrations aim to eliminate barriers to EHR advertising, allowing inclusion in omni-channel strategies via standard DSP workflows.